Actively Recruiting
Phase 1 Study of ZW251, an Antibody-Drug Therapy Targeting Glypican-3, for Advanced Liver, Lung, and Germ Cell Cancers
Led by Zymeworks BC Inc. · Updated on 2026-05-07
100
Participants Needed
25
Research Sites
34 weeks
Total Duration
AI-Summary
What this Trial Is About
Researchers are evaluating ZW251, an antibody-drug conjugate targeting glypican-3 GPC3, in people with advanced cancers such as hepatocellular carcinoma HCC, squamous cell non-small cell lung cancer NSCLC, and germ cell tumors GCT. The study aims to assess whether ZW251 is safe and can treat these cancers. This is a phase 1, open-label, multicenter trial sponsored by Zymeworks BC Inc. The study has two parts Part 1 focuses on dose escalation to test the safety and tolerability of ZW251 in participants with HCC, squamous cell NSCLC, and GCT. Part 2 involves dose optimization to further evaluate safety and potential anti-tumor effects of the recommended doses in participants with HCC. ZW251 is administered intravenously during the study. Participants will be monitored for dose-limiting toxicities, adverse events, laboratory abnormalities, and tumor responses for up to approximately two years. Researchers will assess tumor size changes, disease control, response duration, and progression-free survival. Blood samples will be taken to measure drug concentration and immune reactions. Safety and treatment effects will be closely followed throughout the study.
CONDITIONS
Brief Title
A Study of ZW251 in Participants With Advanced Solid Tumors
Research Team
Z
Zymeworks Clinical Trial Resource
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
